Category: Intellectual property
-
Analysis Uncovers Biotech Commercialization Bottlenecks
21 August 2014. The path from scientific discovery in an academic lab to the marketplace is rarely a straightforward process, with researchers and entrepreneurs often facing detours and delays keeping new biomedical technologies in limbo for years at a time. Those are the conclusions of faculty at Georgia Institute of Technology’s business school that studied…
-
Licensing Deal Combines Genomics, Placenta Stem Cells
11 August 2014. A new licensing agreement will make available research by Celgene Cellular Therapeutics on stem cells from the placenta to Human Longevity Inc., a company specializing in genomics for age-related disorders. Financial aspects of the agreement were not disclosed, but as part of the deal, Celgene is expected to make an equity investment…
-
U.S. Patent Awarded for Prodrug Cancer Imaging, Treatment
30 July 2014. A new patent was awarded for a technology that detects and treats solid tumor cancers with a prodrug, a precursor compound activated inside the body — made by GenSpera Inc., a biotechnology company in San Antonio. U.S. patent number 8,772,226 was awarded on 8 July to inventors Samuel Denmeade and John Isaacs…
-
Arcadia Awarded U.S. Patent for Longer Shelf-Life Tomato
17 July 2014. Arcadia Biosciences, an agricultural biotechnology company in Davis, California received a patent for its engineered tomato that ripens slower after harvesting. Patent number 8,772,606, “Non-transgenic tomato varieties having increased shelf life post-harvest,” was awarded by the U.S. Patent and Trademark Office on 8 July to two inventors and assigned to Arcadia Biosciences.…
-
Novartis Licensing Smart Lens Technology from Google
15 July 2014. The Alcon division of pharmaceutical company Novartis is licensing the rights to Google’s so-called smart lens technology for medical applications involving the eyes. Financial terms of the licensing agreement between Alcon that develops vision care products for Novartis and Google[x], part of the company’s research labs, were not disclosed. Google[x] announced in…
-
University Offers Tuberculosis Drug Technology for Licensing
2 July 2014. A new process for developing drugs for tuberculosis designed at ETH Zurich, the Swiss Federal Institute of Technology, is offered for licensing by the university to companies for commercialization. The technology that aims to overcome resistance to many current tuberculosis drugs is the result of research from the lab of Zurich pharmaceutical…
-
Spin-Off Licenses Genomic Technology from Wash. University
30 June 2014. PierianDx, a new company formed by medical faculty and practitioners at Washington University in St. Louis, licensed genomic technology from the university to commercialize diagnostic tools for personalized medicine. Financial details of the licensing deal were not disclosed. The start-up company plans to offer the technology in a system developed internally by…
-
Fibrocell Science Licenses Stem Cell Technology from UCLA
17 June 2014. The biotechnology company Fibrocell Science Inc. in Exton, Pennsylvania is licensing stem cell discoveries from University of California in Los Angeles for personalized treatments of serious bone and connective tissue conditions. Financial aspects of the licensing deal were not disclosed. Fibrocell Science develops treatments for rare and serious conditions affecting bones, connective…
-
Patent Awarded for Spinal Disc Regeneration Technology
20 May 2014. Techniques for regrowing new spinal disc cartilage tissue in the body from a person’s own skin cells received a patent from the U.S. Patent and Trademark Office. Patent number 8,728,495 was awarded today to inventors Lionel Sevrain and Sylvie Sevrain-Verdier and assigned to SpinalCyte LLC in Houston. Sevrain and Sevrain-Verdier are principals…
-
Regeneron, Avalanche to Partner on Eye Disorder Gene Therapy
5 May 2014. Regeneron Pharmaceuticals in Tarrytown, New York is licensing gene therapy technology from Avalanche Biotechnologies in Menlo Park, California to develop and commercialize new treatments for eye diseases. The value of the deal is at least $640 million, but not all payment amounts were disclosed. Regeneron is a biopharmaceutical company developing therapies for inflammation, cardiovascular and metabolic disorders, cancer,…